Niemann–Pick type C pathogenesis and treatment: from statins to sugars

Bibliography

• Munkacsi A, Porto A, Sturley S: Niemann–Pick type C disease proteins: orphan transporters or membrane rheostats? Future Lipidol. 2(3), 357–367 (2007).
   Google Scholar
• Sturley SL, Patterson MC, Balch W, Liscum L: The pathophysiology and mechanisms of NP‑C disease. Biochim. Biophys. Acta 1685(1–3), 83–87 (2004).
   Google Scholar
• Pentchev PG, Boothe AD, Kruth HS, Weintroub H, Stivers J, Brady RO: A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol. J. Biol. Chem. 259(9), 5784–5791 (1984).
   Google Scholar
• ▪▪ First study to describe cholesterol accumulation in Niemann–Pick type C (NP‑C) disease.
   Google Scholar
• Carstea ED, Morris JA, Coleman KG et al.: Niemann–Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277(5323), 228–231 (1997).
   Google Scholar
• ▪▪ Isolation of the defective gene in human NP‑C disease.
   Google Scholar
• Loftus SK, Morris JA, Carstea ED et al.: Murine model of Niemann–Pick C disease: mutation in a cholesterol homeostasis gene.Science 277(5323), 232–235 (1997).
   Google Scholar
• Naureckiene S, Sleat DE, Lackland H et al.: Identification of HE1 as the second gene of Niemann–Pick C disease. Science 290(5500), 2298–2301 (2000).
   Google Scholar
• Liscum L, Sturley SL: Intracellular trafficking of Niemann–Pick C proteins 1 and 2: obligate components of subcellular lipid transport. Biochim. Biophys. Acta 1685(1–3), 22–27 (2004).
   Google Scholar
• Kwon HJ, Abi‑Mosleh L, Wang ML et al.: Structure of N‑terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol.Cell 137(7), 1213–1224 (2009).
   Google Scholar
• Friedland N, Liou HL, Lobel P, Stock AM: Structure of a cholesterol‑binding protein deficient in Niemann–Pick type C2 disease.Proc. Natl Acad. Sci. USA 100(5), 2512–2517 (2003).
   Google Scholar
• Ohgami N, Ko DC, Thomas M, Scott MP, Chang CC, Chang TY: Binding between the Niemann–Pick C1 protein and a photoactivatable cholesterol analog requires a functional sterol‑sensing domain. Proc. Natl Acad. Sci. USA 101(34), 12473–12478 (2004).
   Google Scholar
• Ko DC, Binkley J, Sidow A, Scott MP: The integrity of a cholesterol‑binding pocket in Niemann–Pick C2 protein is necessary to control lysosome cholesterol levels. Proc. Natl Acad. Sci. USA 100(5), 2518–2525 (2003).
   Google Scholar
• Pentchev PG: Niemann–Pick C research from mouse to gene. Biochim. Biophys. Acta 1685(1–3), 3–7 (2004).
   Google Scholar
• Malathi K, Higaki K, Tinkelenberg AH et al.: Mutagenesis of the putative sterol‑sensing domain of yeast Niemann Pick C‑related protein reveals a primordial role in subcellular sphingolipid distribution. J. Cell Biol. 164(4), 547–556 (2004).
   Google Scholar
• Berger AC, Vanderford TH, Gernert KM, Nichols JW, Faundez V, Corbett AH: Saccharomyces cerevisiae Npc2p is a functionally conserved homologue of the human Niemann–Pick disease type C 2 protein, hNPC2. Eukaryotic cell 4(11), 1851–1862 (2005).
   Google Scholar
• Higaki K, Almanzar‑Paramio D, Sturley SL: Metazoan and microbial models of Niemann–Pick Type C disease. Biochim. Biophys. Acta 1685(1–3), 38–47 (2004).
   Google Scholar
• Brown DE, Thrall MA, Walkley SU et al.: Feline Niemann–Pick disease type C. Am. J. Pathol. 144(6), 1412–1415 (1994).
   Google Scholar
• Vite CH, Ding W, Bryan C et al.: Clinical, electrophysiological, and serum biochemical measures of progressive neurological and hepatic dysfunction in feline Niemann–Pick type C disease. Pediatr. Res. 64(5), 544–549 (2008).
   Google Scholar
• Wraith JE, Baumgartner MR, Bembi B et al.: Recommendations on the diagnosis and management of Niemann–Pick disease type C. Mol. Genet. Metab. 98(1–2), 152–165 (2009).
   Google Scholar
• Imrie J, Dasgupta S, Besley GT et al.: The natural history of Niemann–Pick disease type C in the UK. J. Inherit. Metab. Dis. 30(1), 51–59 (2007).
   Google Scholar
• Falk T, Garver WS, Erickson RP, Wilson JM, Yool AJ: Expression of Niemann–Pick type C transcript in rodent cerebellum in vivo and in vitro. Brain Res. 839(1), 49–57 (1999).
   Google Scholar
• Higashi Y, Murayama S, Pentchev PG, Suzuki K: Cerebellar degeneration in the Niemann–Pick type C mouse. Acta Neuropathol. 85(2), 175–184 (1993).
   Google Scholar
• Walkley SU, Suzuki K: Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim. Biophys. Acta 1685(1–3), 48–62 (2004).
   Google Scholar
• Patel SC, Suresh S, Kumar U et al.: Localization of Niemann–Pick C1 protein in astrocytes: implications for neuronal degeneration in Niemann–Pick type C disease. Proc. Natl Acad. Sci. USA 96(4), 1657–1662 (1999).
   Google Scholar
• Elrick MJ, Pacheco CD, Yu T et al.: Conditional Niemann–Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum. Mol. Genet. 19(5), 837–847 (2010).
   Google Scholar
• Suzuki M, Sugimoto Y, Ohsaki Y et al.: Endosomal accumulation of Toll‑like receptor 4 causes constitutive secretion of cytokines and activation of signal transducers and activators of transcription in Niemann–Pick disease type C (NPC) fibroblasts: a potential basis for glial cell activation in the NPC brain. J. Neurosci. 27(8), 1879–1891 (2007).
   Google Scholar
• Patterson MC, Platt F: Therapy of Niemann–Pick disease, type C. Biochim. Biophys. Acta 1685(1–3), 77–82 (2004).
   Google Scholar
• Koudinov AR, Koudinova NV: Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J. Neurol. Sci. 229–230, 233–240 (2005).
   Google Scholar
• Patterson MC, Di Bisceglie AM, Higgins JJ et al.: The effect of cholesterol‑lowering agents on hepatic and plasma cholesterol in Niemann–Pick disease type C. Neurology 43(1), 61–64 (1993).
   Google Scholar
• Erickson RP, Garver WS, Camargo F, Hossain GS, Heidenreich RA: Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann–Pick C mice. J. Inherit. Metab. Dis. 23(1), 54–62 (2000).
   Google Scholar
• Reid PC, Lin S, Vanier MT et al.: Partial blockage of sterol biosynthesis with a squalene synthase inhibitor in early postnatal Niemann–Pick type C npcnih null mice brains reduces neuronal cholesterol accumulation, abrogates astrogliosis, but may inhibit myelin maturation. J. Neurosci. Methods 168(1), 15–25 (2008).
   Google Scholar
• Liu B, Li H, Repa JJ, Turley SD, Dietschy JM: Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J. Lipid Res. 49(3), 663–669 (2008).
   Google Scholar
• Platt FM, Jeyakumar M: Substrate reduction therapy. Acta Paediatr. Suppl. 97(457), 88–93 (2008).
   Google Scholar
• Elstein D, Hollak C, Aerts JM et al.: Sustained therapeutic effects of oral miglustat (Zavesca, N‑butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J. Inherit. Metab. Dis. 27(6), 757–766 (2004).
   Google Scholar
• Zervas M, Somers KL, Thrall MA, Walkley SU: Critical role for glycosphingolipids in Niemann–Pick disease type C. Curr. Biol. 11(16), 1283–1287 (2001).
   Google Scholar
• ▪ First assessment of glycolipid reduction therapy in NP‑C.
   Google Scholar
• Wraith JE, Imrie J: New therapies in the management of Niemann–Pick type C disease: clinical utility of miglustat. Ther. Clin. Risk Manag. 5, 877–887 (2009).
   Google Scholar
• Patterson MC, Vecchio D, Jacklin E et al.: Long‑term miglustat therapy in children with Niemann–Pick disease type C. J. Child Neurol. 25(3), 300–305 (2010).
   Google Scholar
• Galanaud D, Tourbah A, Lehericy S et al.: 24 month‑treatment with miglustat of three patients with Niemann–Pick disease type C: follow up using brain spectroscopy. Mol. Genet. Metab. 96(2), 55–58 (2009).
   Google Scholar
• Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE: Miglustat for treatment of Niemann–Pick C disease: a randomised controlled study. Lancet Neurol. 6(9), 765–772 (2007).
   Google Scholar
• Wojtal K, Trojnar MK, Czuczwar SJ: Endogenous neuroprotective factors: neurosteroids. Pharmacol. Rep. 58(3), 335–340 (2006).
   Google Scholar
• Mellon S, Gong W, Griffin LD: Niemann pick type C disease as a model for defects in neurosteroidogenesis. Endocr. Res. 30(4), 727–735 (2004).
   Google Scholar
• Griffin LD, Gong W, Verot L, Mellon SH: Niemann–Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat. Med. 10(7), 704–711 (2004).
   Google Scholar
• Ahmad I, Lope‑Piedrafita S, Bi X et al.: Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann–Pick C mice. J. Neurosci. Res 82(6), 811–821 (2005).
   Google Scholar
• Davidson CD, Ali NF, Micsenyi MC et al.: Chronic cyclodextrin treatment of murine Niemann–Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE 4(9), E6951 (2009).
   Google Scholar
• ▪ Synergistic outcome of combined treatments.
   Google Scholar
• Camargo F, Erickson RP, Garver WS et al.: Cyclodextrins in the treatment of a mouse model of Niemann–Pick C disease. Life Sci. 70(2), 131–142 (2001).
   Google Scholar
• Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy JM: Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1‑/‑ mouse. Proc. Natl Acad. Sci. USA 106(7), 2377–2382 (2009).
   Google Scholar
• ▪ First demonstration that clearance from the lysosomal compartment by cyclodextrin was beneficial in the murine model.
   Google Scholar
• Abi‑Mosleh L, Infante RE, Radhakrishnan A, Goldstein JL, Brown MS: Cyclodextrin overcomes deficient lysosome‑to‑endoplasmic reticulum transport of cholesterol in Niemann–Pick type C cells. Proc. Natl Acad. Sci. USA 106(46), 19316–19321 (2009).
   Google Scholar
• Hsu YS, Hwu WL, Huang SF et al.: Niemann–Pick disease type C (a cellular cholesterol lipidosis) treated by bone marrow transplantation. Bone Marrow Transplant. 24(1), 103–107 (1999).
   Google Scholar
• Bae JS, Furuya S, Ahn SJ, Yi SJ, Hirabayashi Y, Jin HK: Neuroglial activation in Niemann–Pick Type C mice is suppressed by intracerebral transplantation of bone marrow‑derived mesenchymal stem cells.Neurosci Lett. 381(3), 234–236 (2005).
   Google Scholar
• Kim SJ, Lim MS, Kang SK, Lee YS, Kang KS: Impaired functions of neural stem cells by abnormal nitric oxide‑mediated signaling in an in vitro model of Niemann–Pick type C disease. Cell Res. 18(6), 686–694 (2008).
   Google Scholar
• Ahmad I, Hunter RE, Flax JD, Snyder EY, Erickson RP: Neural stem cell implantation extends life in Niemann–Pick C1 mice.J. Appl. Genet. 48(3), 269–272 (2007).
   Google Scholar
• Repa JJ, Li H, Frank‑Cannon TC et al.: Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J. Neurosci. 27(52), 14470–14480 (2007).
   Google Scholar
• Choudhury A, Dominguez M, Puri V et al.: Rab proteins mediate Golgi transport of caveola‑internalized glycosphingolipids and correct lipid trafficking in Niemann–Pick C cells. J. Clin. Invest. 109(12), 1541–1550 (2002).
   Google Scholar
• Narita K, Choudhury A, Dobrenis K et al.: Protein transduction of Rab9 in Niemann–Pick C cells reduces cholesterol storage.FASEB J. 19(11), 1558–1560 (2005).
   Google Scholar
• Ganley IG, Pfeffer SR: Cholesterol accumulation sequesters Rab9 and disrupts late endosome function in NPC1‑deficient cells.J. Biol. Chem. 281(26), 17890–17899 (2006).
   Google Scholar
• Walter M, Chen FW, Tamari F, Wang R, Ioannou YA: Endosomal lipid accumulation in NPC1 leads to inhibition of PKC, hypophosphorylation of vimentin and Rab9 entrapment. Biol. Cell 101(3), 141–152 (2009).
   Google Scholar
• Kaptzan T, West SA, Holicky EL et al.: Development of a Rab9 transgenic mouse and its ability to increase the lifespan of a murine model of Niemann–Pick type C disease. Am. J. Pathol. 174(1), 14–20 (2009).
   Google Scholar
• Noble W, Planel E, Zehr C et al.: Inhibition of glycogen synthase kinase‑3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102(19), 6990–6995 (2005).
   Google Scholar
• Bu B, Li J, Davies P, Vincent I: Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann–Pick type C murine model. J. Neurosci. 22(15), 6515–6525 (2002).
   Google Scholar
• Mapelli M, Massimiliano L, Crovace C et al.: Mechanism of CDK5/p25 binding by CDK inhibitors. J. Med. Chem. 48(3), 671–679 (2005).
   Google Scholar
• Zhang M, Li J, Chakrabarty P, Bu B, Vincent I: Cyclin‑dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann–Pick Type C mice. Am. J. Pathol. 165(3), 843–853 (2004).
   Google Scholar
• Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM: Beneficial effects of anti‑inflammatory therapy in a mouse model of Niemann–Pick disease type C1. Neurobiol. Dis. 36(2), 242–251 (2009).
   Google Scholar
• Somers KL, Brown DE, Fulton R et al.: Effects of dietary cholesterol restriction in a feline model of Niemann–Pick type C disease.J. Inherit. Metab. Dis. 24(4), 427–436 (2001).
   Google Scholar
• Li H, Repa JJ, Valasek MA et al.: Molecular, anatomical, and biochemical events associated with neurodegeneration in mice with Niemann–Pick type C disease. J. Neuropathol. Exp. Neurol. 64(4), 323–333 (2005).
   Google Scholar
• Zampieri S, Mellon SH, Butters TD et al.: Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone. J. Cell Mol. Med. 13(9B), 3786–3796 (2009).
   Google Scholar
• Bascunan‑Castillo EC, Erickson RP, Howison CM et al.: Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann–Pick C. J. Appl. Genet. 45(4), 461–467 (2004).
   Google Scholar
• Lloyd‑Evans E, Morgan AJ, He X et al.: Niemann–Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14(11), 1247–1255 (2008).
   Google Scholar
• Wang MS, Boddapati S, Sierks MR: Cyclodextrins promote protein aggregation posing risks for therapeutic applications.Biochem. Biophys. Res. Commun. 386(3), 526–531 (2009).
   Google Scholar
• Vanier MT: Biochemical studies in Niemann–Pick disease. I. Major sphingolipids of liver and spleen. Biochim. Biophys. Acta 750(1), 178–184 (1983).
   Google Scholar
• Vanier MT: Lipid changes in Niemann–Pick disease type C brain: personal experience and review of the literature. Neurochem. Res. 24(4), 481–489 (1999).
   Google Scholar
• Rodriguez‑Lafrasse C, Rousson R, Pentchev PG, Louisot P, Vanier MT: Free sphingoid bases in tissues from patients with type C Niemann–Pick disease and other lysosomal storage disorders.Biochim. Biophys. Acta 1226(2), 138–144 (1994).
   Google Scholar
• Rimkunas VM, Graham MJ, Crooke RM, Liscum L: TNF‑a plays a role in hepatocyte apoptosis in Niemann–Pick type C liver disease. J. Lipid Res. 50(2), 327–333 (2009).
   Google Scholar
• Goldin E, Roff CF, Miller SP et al.: Type C Niemann–Pick disease: a murine model of the lysosomal cholesterol lipidosis accumulates sphingosine and sphinganine in liver.Biochim. Biophys. Acta 1127(3), 303–311 (1992).
   Google Scholar
• Xie C, Turley SD, Pentchev PG, Dietschy JM: Cholesterol balance and metabolism in mice with loss of function of Niemann–Pick C protein. Am. J. Physiol. 276(2 Pt 1), E336–E344 (1999).
   Google Scholar
• Lowenthal AC, Cummings JF, Wenger DA, Thrall MA, Wood PA, De Lahunta A: Feline sphingolipidosis resembling Niemann–Pick disease type C. Acta Neuropathol. 81(2), 189–197 (1990).
   Google Scholar